Eton Pharmaceuticals Stock Earnings Reports

Eton reported a strong Q1 2026 driven by 73% year-over-year product revenue growth to $24.3M, led by INCRELEX, ALKINDI, GALZIN and Carglumic Acid. The company launched two major products in 2026 — DESMODA (desmopressin oral solution) and HEMANGEOL (only FDA‑approved therapy for infantile hemangiomas) — and raised 2026 revenue guidance to >$120M (from $110M) based on Q1 outperformance and early Q2 trends. Adjusted EBITDA was $5.7M (24% of revenue) with management reiterating expectations of >30% adjusted EBITDA margin for full‑year 2026 and a long‑term goal of 50% adjusted EBITDA margin by 2028. Eton emphasized its rare‑disease commercialization model, centralized specialty distribution, and patient‑support initiatives (Eton Cares) to accelerate access and conversions. For HEMANGEOL, management expects a substantial proportion of patients to have near‑zero net revenue (estimated ~60–65% of volume), leading to an estimated average net price per full course of $8K–$10K; meaningful revenue from the relaunch is expected to ramp into Q3 2026, with potential to be the company’s largest product in 2027. DESMODA launch reception has been positive and management believes peak sales could reach $30M–$50M. R&D progress includes FDA clearance to proceed with an INCRELEX label harmonization trial (to start H2 2026), a pilot study for ET‑700 with top‑line readout expected H2 2026, KHINDIVI bioequivalence dosing wrap‑up (potential supplemental filing in Q3 2026), and an IND filed for Amglidia with an anticipated NDA submission in Q4 2026. Financially, adjusted gross margin remains targeted at ≥70% for 2026, cash on hand was $19.7M at quarter end after a $14M HEMANGEOL acquisition payment, and the company amended its $30M credit facility to lower interest by ~200 bps. Management plans continued disciplined M&A and expects significant excess cash generation to support accretive product acquisitions. Key risks noted include launch uncertainties, patient mix/coverage dynamics for HEMANGEOL, and quarter‑to‑quarter fluctuations tied to R&D timing and ex‑U.S. orders.